Holen Sie sich die Stockscreener-App
20.93
2.55%
0.52
Handel nachbörslich:
20.93
Schlusskurs vom Vortag:
$20.41
Offen:
$20.49
24-Stunden-Volumen:
330.85K
Relative Volume:
0.89
Marktkapitalisierung:
$776.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.14%
1M Leistung:
+62.88%
6M Leistung:
+15.13%
1J Leistung:
-28.32%
1-Tages-Spanne:
$20.20
$21.07
1-Wochen-Bereich:
$19.52
$24.25
52-Wochen-Spanne:
$10.01
$29.96
Ceribell Inc Stock (CBLL) Company Profile
Firmenname
Ceribell Inc
Sektor
Branche
Telefon
(800) 436-0826
Adresse
360 N. PASTORIA AVENUE, SUNNYVALE
Vergleichen Sie CBLL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
20.93 | 757.12M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-24 | Eingeleitet | BTIG Research | Buy |
| 2025-04-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-11-05 | Eingeleitet | BofA Securities | Buy |
| 2024-11-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Ceribell Inc Aktie (CBLL) Neueste Nachrichten
Ceribell extends leases for Sunnyvale offices through January 2028 By Investing.com - Investing.com Nigeria
FDA Clears Ceribell’s AI-Powered EEG as First Device for Continuous Delirium Monitoring - HIT Consultant
Ceribell, Inc. Extends Sunnyvale Office Leases - TipRanks
Ceribell extends leases for Sunnyvale offices through January 2028 - Investing.com
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution - TradingView
Ceribell receives FDA 510K clearance for delirium screening, monitoring device - MSN
Risk Analysis: Will CeriBell Inc stock split attract more investorsEarnings Miss & Verified Short-Term Trading Plans - moha.gov.vn
Ceribell director Robertson sells $100k in CBLL stock By Investing.com - Investing.com South Africa
Ceribell director Robertson sells $100k in CBLL stock - Investing.com
FDA OKs Ceribell’s Delirium Monitoring Solution - Medical Product Outsourcing
Buy Rating Affirmed for Ceribell, Inc. Due to Innovative Neonate Technology and FDA Clearance - TipRanks
Ceribell, Inc.’s Delirium Solution Gains Early FDA Clearance, Boosting Market Potential and Supporting Buy Rating - TipRanks
There's Reason For Concern Over CeriBell, Inc.'s (NASDAQ:CBLL) Massive 69% Price Jump - 富途牛牛
Ceribell stock price target raised to $29 from $20 at TD Cowen on FDA clearance - Investing.com
CeriBell Says FDA Clears Delirium Monitoring Solution; Shares Rise - marketscreener.com
Ceribell, Inc. Gains FDA Clearance for Delirium Device - TipRanks
Ceribell jumps on FDA clearance of brain monitoring device - TradingView
Ceribell, Inc. Receives FDA Clearance for Delirium Monitoring Solution - TradingView
Ceribell receives FDA 510k clearance for delirium screening, monitoring device - TipRanks
FDA clears Ceribell’s delirium monitoring system for ICU patients - Investing.com
FDA clears Ceribell’s delirium monitoring system for ICU patients By Investing.com - Investing.com India
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution - The Manila Times
Ceribell CEO Chao Xingjuan sells $470k in CBLL stock By Investing.com - Investing.com Canada
CeriBell (NASDAQ:CBLL) CEO Sells $470,500.00 in Stock - MarketBeat
Ceribell CEO Chao Xingjuan sells $470k in CBLL stock - Investing.com
Ceribell Insider Sold Shares Worth $470,500, According to a Recent SEC Filing - marketscreener.com
David Foehr Sells 5,265 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell’s Foehr David sells $88k in Ceribell stock By Investing.com - Investing.com Australia
Ceribell’s Foehr David sells $88k in Ceribell stock - Investing.com India
Ceribell Senior VP David Foehr Sells 5,265 Shares - TradingView
VP Foehr Sells 5,265 ($88.6K) Of CeriBell Inc [CBLL] - TradingView
Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells 827 Shares of Stock - MarketBeat
Geode Capital Management LLC Has $8.39 Million Stock Position in CeriBell, Inc. $CBLL - MarketBeat
CEO Chao Files To Sell 25,000 Of CeriBell Inc [CBLL] - TradingView
Robertson of Ceribell sells $13k in shares By Investing.com - Investing.com Nigeria
Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells 25,000 Shares of Stock - MarketBeat
CeriBell (NASDAQ:CBLL) CTO Sells $136,455.36 in Stock - MarketBeat
Robertson of Ceribell sells $13k in shares - Investing.com
Ceribell Director Rebecca B. Robertson Sells 827 Shares - TradingView
Chmn Robertson Sells 827 ($13.8K) Of CeriBell Inc [CBLL] - TradingView
CeriBell, Inc. (CBLL) Presents at Piper Sandler 37th Annual Healthcare ConferenceSlideshow - Seeking Alpha
Ceribell management to meet virtually with BTIG - MSN
Ceribell’s Woo Raymond sells $136k in shares By Investing.com - Investing.com Australia
Ceribell’s Woo Raymond sells $136k in shares - Investing.com
Ceribell Insider Sold Shares Worth $414,750, According to a Recent SEC Filing - marketscreener.com
Officer Woo Sells 11,112 ($184.5K) Of CeriBell Inc [CBLL] - TradingView
CEO Chao Sells 25,000 ($414.8K) Of CeriBell Inc [CBLL] - TradingView
CBLL: AI-driven EEG platform posts robust growth, expands indications, and demonstrates clinical impact - TradingView
Aug Sectors: Is CeriBell Inc stock a buy on dipsMarket Weekly Review & Weekly Chart Analysis and Guides - BỘ NỘI VỤ
Finanzdaten der Ceribell Inc-Aktie (CBLL)
Es liegen keine Finanzdaten für Ceribell Inc (CBLL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):